Metabolic syndrome associated with HIV and highly active antiretroviral therapy

Current Diabetes Reports

Volumn 9, Issue 1, 2009, Pages 37-42

  Barbaro, Giuseppe ^a   Iacobellis, Gialuca ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ABACAVIR; ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OMEGA 3 FATTY ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPOPROTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LACTATE BLOOD LEVEL; LIPID METABOLISM; LIPOLYSIS; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SURVIVAL RATE;

ADIPOKINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERTENSION; LIPODYSTROPHY; METABOLIC SYNDROME X; MITOCHONDRIA; PROTEASE INHIBITORS; RISK ASSESSMENT; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59849124169     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0008-7     Document Type: Review

References (49)

1. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
3. Samaras K, Wand H, Law M, et al.: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international Diabetes Foundation and Adult Treatment Panel III criteria: Association with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and hypoadiponectinemia. Diabetes Care 2007, 30:113-119.
4. Wand H, Calmy A, Carey DL, et al.: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
5. Gougeon ML, Penicaud L, Fromenty B, et al.: Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004, 9:161-177.
6. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
7. Fauvel J, Bonnet E, Ruidavets JB, et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/ low HDL levels in treated HIV patients. AIDS 2001, 15:2397-2406.
8. Bonnet E, Ruidavets JB, Tuech J, et al.: Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J Clin Endocrinol Metab 2001, 86:296-302.
9. Caron M, Auclair M, Sterlingot H, et al.: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003, 17:2437-2444.
10. Jones SP, Janneh O, Back DJ, Pirmohammed M: Altered adipocytokines gene expression in murine 3T3-F442A adipocyte treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2003, 8:L11.
11. Myarcik DC, McNurlan MA, Steigbigel RT, et al.: Association of severe insulin resistance with body loss and limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J AIDS 2000, 25:312-321.
12. Rietschel P, Hadigan C, Corcoran C, et al.: Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Clin Endocrinol Metab 2001, 86:504-510.
13. Lo JC, Mulligan K, Noor MA, et al.: The effect of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001, 86:3480-3487.
14. Caron M, Auclair M, Lagathu C, et al.: The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte function in vitro. AIDS 2004, 18:2127-2136.
15. Villarroya F, Domingo P, Giralt M: Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: The adipocyte as target of antiretroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005, 26:88-93.
16. Lewis W, Kohler J, Hosseini S, et al.: Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol-gamma hypothesis. AIDS 2006, 20:675-684.
17. Seminari E, Tinelli C, Minoli L, et al.: Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther 2002, 7:175-180.
18. McComsey GA, Paulsen D, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15-23.
19. Vigouroux C, Maachi M, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003, 17:1503-1511.
20. Haque WA, Shimomura I, Matsuzawa Y, Garg A: Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395-2398.
21. Addy CL, Gavrila A, Tsiodras S, et al.: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003, 88:627-636.
22. Hadigan C, Meigs JB, Rabe J, et al.: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939-943.
23. Witz M, Lehmann J, Korzets Z: Acute brachial artery thrombosis as the initial manifestations of human immunodeficiency virus infection. Am J Hematol 2000, 64:137-139.
24. Sullivan PS, Dworkin MS, Jones JL, Hooper WC: Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000, 14:321-324.
25. Fiala M, Murphy T, MacDougall J, et al.: HAART drugs induces mitochondrial damage and intercellular gaps ans gp120 causes apoptosis. Cardiovasc Toxicol 2005, 4:327-337.
26. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
27. Zhong DS, Lu XH, Conklin BS, et al.: HIV protease ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:1560-1566.
28. Roling J, Schmid H, Fischereder M, et al.: HIV-associated renal diseases and highly active antiretriviral therapyinduced nephropathy. Clin Infect Dis 2006, 42:1488-1495.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
30. Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: Prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377-1382.
31. Sattler FR, Qian D, Louie S, et al.: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001, 15:2001-2010.
32. Maggi P, Serio G, Epifani G, et al.: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000, 14:F123-F128.
33. Depairon M, Chessex S, Sudre P, et al.: Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy. AIDS 2001, 15:329-334.
34. Hsue PY, Lo JC, Franklin A, et al.: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109:1603-1608.
35. Currier JS, Kendall MA, Zackin R, et al.: Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005, 19:927-933.
36. Jerico C, Knobel H, Calvo N, et al.: Subclinical carotid atherosclerosis in HIV-infected patients: Role of combination antiretroviral therapy. Stroke 2006, 37:812-817.
37. Holmberg SD, Moorman AC, Williamson JM, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
38. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
39. Mary-Krause M, Cotte L, Simon A, et al.: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479-2486.
40. Barbaro G, Di Lorenzo G, Cirelli A, et al.: An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 2003, 25:2405-2418.
41. The DAD Study Group, Friis-Møller N, Reiss P, et al.: Class of antiretriviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
42. Dubé MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin Infect Dis 2004, 37:613-627.
43. Volberding P, Murphy R, Barbaro G, et al.: The pavia consensus statement. AIDS 2003, 17(Suppl 1):S170-S179.
44. Iacobellis G, Sharma AM, Pellicelli AM, et al.: Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007, 5:275-279.
45. Iacobellis G, Pellicelli AM, Sharma AM, et al.: Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 2007, 99:1470-1472.
46. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med 2005, 143:337-346.
47. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomized, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
48. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized controlled trial. Ann Intern Med 2004, 140:786-794.
49. Cavalcanti RB, Raboud J, Shen S, et al.: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007, 195:1754-1761.